Payment overview · 2025
General Payments
$27.52
2 reported records · 1 companies
Healthcare provider profile · identity verified
Changxin Li, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GAYLORD, MI · NPI 1114958899
Verified facts
What the public records show
CMS Open Payments records show Changxin Li, M.D. received $27.52 in general payments during 2025 across 2 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $27.52 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $27.52 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $27.52 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 589 | 168 |
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 172 |
| Lisinopril | Lisinopril | 435 | 132 |
| Omeprazole | Omeprazole | 397 | 119 |
| Metformin Hcl | Metformin Hcl | 390 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 324 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 97 |
| Losartan Potassium | Losartan Potassium | 240 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 66 |
| Gabapentin | Gabapentin | 215 | 68 |
| Furosemide | Furosemide | 209 | 85 |
| Eliquis | Apixaban | 182 | 52 |
| Ozempic | Semaglutide | 173 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 160 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 160 | 44 |
| Tramadol Hcl | Tramadol Hcl | 157 | 32 |
| Jardiance | Empagliflozin | 153 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 46 |
| Mounjaro | Tirzepatide | 148 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 57 |
| Sertraline Hcl | Sertraline Hcl | 134 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 133 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 41 |
| Glimepiride | Glimepiride | 124 | 38 |
| Simvastatin | Simvastatin | 124 | 35 |
| Alprazolam | Alprazolam | 123 | 33 |
| Potassium Chloride | Potassium Chloride | 117 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 37 |
| Allopurinol | Allopurinol | 113 | 25 |
| Finasteride | Finasteride | 113 | 37 |
| Trazodone Hcl | Trazodone Hcl | 108 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 105 | 34 |
| Aripiprazole | Aripiprazole | 103 | 26 |
| Prednisone | Prednisone | 99 | 66 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 31 |
| Carvedilol | Carvedilol | 87 | 33 |
| Atenolol | Atenolol | 81 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 18 |
| Ibuprofen | Ibuprofen | 80 | 33 |
| Lorazepam | Lorazepam | 79 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 27 |
| Trulicity | Dulaglutide | 65 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 22 |
| Farxiga | Dapagliflozin Propanediol | 62 | 15 |
| Valsartan | Valsartan | 62 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 14 |
| Montelukast Sodium | Montelukast Sodium | 57 | 21 |
| Pregabalin | Pregabalin | 57 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Spironolactone | Spironolactone | 56 | 18 |
| Buspirone Hcl | Buspirone Hcl | 55 | 14 |
| Glipizide Er | Glipizide | 55 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 15 |
| Ezetimibe | Ezetimibe | 51 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 17 |
| Estradiol | Estradiol | 48 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 20 |
| Methylprednisolone | Methylprednisolone | 44 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 12 |
| Meclizine Hcl | Meclizine Hcl | 42 | 17 |
| Azithromycin | Azithromycin | 41 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 16 |
| Clonazepam | Clonazepam | 39 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 39 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 12 |
| Levetiracetam | Levetiracetam | 38 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 33 |
| Famotidine | Famotidine | 35 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Baclofen | Baclofen | 34 | suppressed |
| Topiramate | Topiramate | 34 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 11 |
| Propranolol Hcl | Propranolol Hcl | 33 | 11 |
| Risperidone | Risperidone | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 17 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Glipizide | Glipizide | 32 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Sucralfate | Sucralfate | 32 | 16 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | 11 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 12 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | 11 |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Metolazone | Metolazone | 20 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27.52 · 2 records | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error